Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- 41 Financing Alzheimer’s Disease Drug Development
- 42 Valley of Death and the Role of Venture Philanthropy in Alzheimer’s Disease Drug Development
- 43 Alzheimer’s Association Funding and Policy for Alzheimer’s Disease Drug Development
- 44 The Role of Philanthropy in Alzheimer’s Disease Therapeutic Development
- 45 National Institute on Aging’s Alzheimer’s Disease Translational Research Program: Diversifying the Drug-Development Pipeline for the Treatment and Prevention of Alzheimer’s Disease and Related Dementias
- 46 Alzheimer ’s Disease Drug Discovery and the Evolution of Start-Up Biotechnology Companies: Cognition Therapeutics, Inc. as a Case Study
- 47 Introduction to Venture Capital in Alzheimer’s Disease Drug Development
- 48 Federal Small Business Support for Small Businesses Pursuing Alzheimer’s Disease Drug Development
- Index
- References
44 - The Role of Philanthropy in Alzheimer’s Disease Therapeutic Development
from Section 7 - Funding and Financing Alzheimer’s Disease Drug Development
Published online by Cambridge University Press: 03 March 2022
By
Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- 41 Financing Alzheimer’s Disease Drug Development
- 42 Valley of Death and the Role of Venture Philanthropy in Alzheimer’s Disease Drug Development
- 43 Alzheimer’s Association Funding and Policy for Alzheimer’s Disease Drug Development
- 44 The Role of Philanthropy in Alzheimer’s Disease Therapeutic Development
- 45 National Institute on Aging’s Alzheimer’s Disease Translational Research Program: Diversifying the Drug-Development Pipeline for the Treatment and Prevention of Alzheimer’s Disease and Related Dementias
- 46 Alzheimer ’s Disease Drug Discovery and the Evolution of Start-Up Biotechnology Companies: Cognition Therapeutics, Inc. as a Case Study
- 47 Introduction to Venture Capital in Alzheimer’s Disease Drug Development
- 48 Federal Small Business Support for Small Businesses Pursuing Alzheimer’s Disease Drug Development
- Index
- References
Summary
Therapeutic development is complex, best compared to capital expenditures for national infrastructural investments. Therapeutic development involves many partners. Alzheimer’s disease therapeutic development has been especially challenging. The disease course is long and slow, the biology complex and elusive, and trials are cumbersome and costly. Nonetheless, scientific understanding and approaches have reached a tipping point that warrant greater attention and investment. In this complex landscape, philanthropy is unlikely to address all challenges, but instead can play critical roles filling in where other funding sources are less suited. In this chapter, we outline four areas for philanthropic investment: therapeutic development prior to clinical testing, ensuring that diverse perspectives remain intellectual contributors to the field, providing personal perspectives to drive priorities toward patient needs, and fostering cultural change in science to promote greater collaboration. These investments are an important part of a larger ecosystem but can play an outsized role in accelerating scientific progress.
Keywords
- Type
- Chapter
- Information
- Alzheimer's Disease Drug DevelopmentResearch and Development Ecosystem, pp. 496 - 502Publisher: Cambridge University PressPrint publication year: 2022
References
Super, N, Ahuja, R, Proff, K. Reducing the cost and risk of dementia. Available at: https://milkeninstitute.org/sites/default/files/reports-pdf/Reducing%20the%20Cost%20and%20Risk%20of%20Dementia%20Full%20Report-FINAL-for-posting_0.pdf (accessed November 25, 2020).Google Scholar
Alzheimer’s Association. 2020 Alzheimer’s disease facts and figures. Alzheimers Dement 2020; 16: 391–460.CrossRefGoogle Scholar
PhRMA. Research. Alzheimer’s medicines: setbacks and stepping stones. Available at: www.phrma.org/en/Alzheimer-s-Medicines-Setbacks-and-Stepping-Stones (accessed November 25, 2020).Google Scholar
Research!America. U.S. Investments in Medical and Health Reserach and Development, 2013–2017. Available at: www.researchamerica.org/sites/default/files/Policy_Advocacy/2013-2017InvestmentReportFall2018.pdf (accessed November 25, 2020).Google Scholar
Milken, M. Giving pledge letter 2010. Available at: https://givingpledge.org/Pledger.aspx?id=245 (accessed November 25, 2020).Google Scholar
Alzheimer’s Impact Movement. Alzheimer’s and dementia research. Available at: https://alzimpact.org/issues/research#:~:text=Today%2C%20funding%20for%20Alzheimer’s%20and,increase%20for%20fiscal%20year%202020 (accessed November 25, 2020).Google Scholar
Losak, A. New coalition of philanthropists including Bill Gates, Leonard Lauder commit more than $30 million. Available at: www.alzdiscovery.org/news-room/announcements/new-coalition-of-philanthropists-including-bill-gates-and-leonard-lauder-co (accessed November 25, 2020).Google Scholar
The Giving Pledge. Giving pledge. 2020. Available at: https://givingpledge.org/PledgerList.aspx (accessed November 25, 2020).Google Scholar
Charette, MF, Oh, YS, Maric-Bilkan, C, et al. Shifting demographics among research project grant awardees at the National Heart, Lung, and Blood Institute (NHLBI). PloS One 2016; 11: e0168511.Google Scholar
Blau, DM, Weinberg, BA. Why the US science and engineering workforce is aging rapidly. PNAS 2017; 114: 3879–84.CrossRefGoogle ScholarPubMed